Renal effects of prostaglandins and cyclooxygenase-2 inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Gheun Ho | - |
dc.date.accessioned | 2022-10-07T10:17:59Z | - |
dc.date.available | 2022-10-07T10:17:59Z | - |
dc.date.created | 2022-09-16 | - |
dc.date.issued | 2008-06 | - |
dc.identifier.issn | 1738-5997 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172008 | - |
dc.description.abstract | "Prostaglandins (PGs) with best-defined renal functions are PGE2 and prostacyclin (PGI2). These vasodilatory PGs increase renal blood flow and glomerular filtration rate under conditions associated with decreased actual or effective circulating volume, resulting in greater tubular flow and secretion of potassium. Under conditions of decreased renal perfusion, the production of renal PGs serves as an important compensatory mechanism. PGI2 (and possibly PGE2) increases potassium secretion mainly by stimulating secretion of renin and activating the renin-angiotensin system, which leads to increased secretion of aldosterone. In addition, PGE2 is involved in the regulation of sodium and water reabsorption and acts as a counterregulatory factor under conditions of increased sodium reabsorption. PGE2 decreases sodium reabsorption at the thick ascending limb of the loop of Henle probably via inhibition of the Na+-K+-2Cl- cotransporter type 2 (NKCC2). Cyclooxygenase inhibitors may enhance urinary concentrating ability in part through effects to upregulate NKCC2 in the thick ascending limb of Henle's loop and aquaporin-2 in the collecting duct. Thus, they may be useful to treat Bartter's syndrome and nephrogenic diabetes insipidus. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Electrolyte and Blood Pressure Research | - |
dc.title | Renal effects of prostaglandins and cyclooxygenase-2 inhibitors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Gheun Ho | - |
dc.identifier.doi | 10.5049/EBP.2008.6.1.35 | - |
dc.identifier.scopusid | 2-s2.0-50849084471 | - |
dc.identifier.bibliographicCitation | Electrolyte and Blood Pressure, v.6, no.1, pp.35 - 41 | - |
dc.relation.isPartOf | Electrolyte and Blood Pressure | - |
dc.citation.title | Electrolyte and Blood Pressure | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 41 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001255666 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordPlus | angiotensin II | - |
dc.subject.keywordPlus | antihypertensive agent | - |
dc.subject.keywordPlus | aquaporin 2 | - |
dc.subject.keywordPlus | beta adrenergic receptor blocking agent | - |
dc.subject.keywordPlus | celecoxib | - |
dc.subject.keywordPlus | cyclooxygenase 1 | - |
dc.subject.keywordPlus | cyclooxygenase 2 | - |
dc.subject.keywordPlus | cyclooxygenase 2 inhibitor | - |
dc.subject.keywordPlus | dipeptidyl carboxypeptidase inhibitor | - |
dc.subject.keywordPlus | diuretic agent | - |
dc.subject.keywordPlus | hydrochlorothiazide | - |
dc.subject.keywordPlus | indometacin | - |
dc.subject.keywordPlus | nonsteroid antiinflammatory agent | - |
dc.subject.keywordPlus | prostacyclin | - |
dc.subject.keywordPlus | prostaglandin E2 | - |
dc.subject.keywordPlus | prostaglandin receptor blocking agent | - |
dc.subject.keywordPlus | prostaglandin synthase inhibitor | - |
dc.subject.keywordPlus | renin | - |
dc.subject.keywordPlus | rofecoxib | - |
dc.subject.keywordPlus | sodium potassium chloride cotransporter | - |
dc.subject.keywordPlus | vasopressin | - |
dc.subject.keywordPlus | aldosterone release | - |
dc.subject.keywordPlus | Bartter syndrome | - |
dc.subject.keywordPlus | blood pressure | - |
dc.subject.keywordPlus | body water | - |
dc.subject.keywordPlus | drug mechanism | - |
dc.subject.keywordPlus | drug potentiation | - |
dc.subject.keywordPlus | enzyme activity | - |
dc.subject.keywordPlus | enzyme inhibition | - |
dc.subject.keywordPlus | enzyme regulation | - |
dc.subject.keywordPlus | feedback system | - |
dc.subject.keywordPlus | food drug interaction | - |
dc.subject.keywordPlus | glomerulus filtration rate | - |
dc.subject.keywordPlus | Henle loop | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hyperkalemia | - |
dc.subject.keywordPlus | hypertension | - |
dc.subject.keywordPlus | kidney blood flow | - |
dc.subject.keywordPlus | kidney failure | - |
dc.subject.keywordPlus | kidney tubule acidosis | - |
dc.subject.keywordPlus | leg edema | - |
dc.subject.keywordPlus | natriuresis | - |
dc.subject.keywordPlus | nephrogenic diabetes insipidus | - |
dc.subject.keywordPlus | nephrotoxicity | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | potassium transport | - |
dc.subject.keywordPlus | protein expression | - |
dc.subject.keywordPlus | renin angiotensin aldosterone system | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | side effect | - |
dc.subject.keywordPlus | sodium absorption | - |
dc.subject.keywordPlus | sodium balance | - |
dc.subject.keywordPlus | sodium retention | - |
dc.subject.keywordPlus | upregulation | - |
dc.subject.keywordPlus | vasoconstriction | - |
dc.subject.keywordPlus | water absorption | - |
dc.subject.keywordAuthor | Kidney | - |
dc.subject.keywordAuthor | Kidney concentrating ability | - |
dc.subject.keywordAuthor | Prostaglandins | - |
dc.subject.keywordAuthor | Sodium | - |
dc.identifier.url | https://synapse.koreamed.org/upload/synapsedata/pdfdata/2158ebp/ebp-6-35.pdf | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.